pharmaceutically acceptable salts) or prodrugs thereof.

~~In one aspect of t~~The present disclosure~~, there is~~ provide~~s~~d a compound of formula (A), wherein,

- cycle A is selected from the group consisting of cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; wherein said cycloalkyl, cycloalkenyl, cycloalkynyl, aryl and heterocycle, can be unsubstituted or substituted with one or more substituents selected from alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, $-OCF_3$, cyano, nitro, -C(O)OH, $-NH_2$, NH(alkyl), or $N(alkyl)_2$;

- cycle C is a monocycle selected from



(a1) ; (a3) ;

wherein the wavy line (~~~~) indicates the point of attachment to the carbonyl of the main formula (A) and the hashed line (||||||||||) indicates the point of attachment to the cycle A of the main formula (A);

- X^1 is selected from C; and N;
- X^2 is selected from CR^{12}; NR^{13}; N; O; and S;
- X^3 is selected from CR^{14}, NR^{15}; N; O; and S;
- X^4 is selected from CR^{16}, NR^{17}; N; O; and S;
- each R^9 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; =O; and =S; wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;
- W^1 is selected from $CR^{32}R^{32a}$; NR^{33}; O; S; and SO_2;
- each p and q is independently selected from 1 and 2, whereby p+q is selected from 2 and 3;
- cycle B is selected from aryl; and heterocycle; wherein said aryl and heterocycle can be unsubstituted or substituted with one or more Z^{1a};
- R^1 is selected from cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; heterocycle; arylalkyl; arylalkenyl; arylalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-heteroalkyl; heterocycle-heteroalkenyl; heterocycle-heteroalkynyl;

and wherein said cycloalkyl; cycloalkenyl; cycloalkynyl; aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl and heterocycle-heteroalkynyl can be unsubstituted or substituted with one or

heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, -O-alkyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

and wherein Z^4 and Z^5 can be taken together in order to form a (5-, 6-, or 7-membered) heterocycle which can be unsubstituted or substituted with alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, hydroxyl, halogen, -SH, trifluoromethyl, -O-alkyl, $-OCF_3$, cyano, nitro, -C(O)OH or $-NH_2$;

and isomers (in particular stereo-isomers or tautomers), solvates, salts (in particular pharmaceutically acceptable salts) or prodrugs thereof,

with the proviso that said compound is not

2-anilino-2-(4-tert-butylphenyl)-1-(2-phenyl-1-piperidyl)ethanone;

2-anilino-1-(2-phenyl-1-piperidyl)-2-[4-(trifluoromethyl)phenyl]ethanone;

2-anilino-2-(4-tert-butylphenyl)-1-(2-phenylazepan-1-yl)ethanone.

In one aspect of the present disclosure, there is provided a compound of formula (A), wherein,

- cycle A is selected from the group consisting of cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; wherein said cycloalkyl, cycloalkenyl, cycloalkynyl, aryl and heterocycle, can be unsubstituted or substituted with one or more substituents selected from alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, $-OCF_3$, cyano, nitro, -C(O)OH, $-NH_2$, NH(alkyl), or $N(alkyl)_2$;

- cycle C is a monocycle selected from



(a1) ; (a3) ;

wherein the wavy line (〰) indicates the point of attachment to the carbonyl of the main formula (A) and the hashed line (||||||||||) indicates the point of attachment to the cycle A of the main formula (A);

- X^1 is selected from C; and N;

- X^2 is selected from CR^{12}; NR^{13}; N; O; and S;

- X^3 is selected from CR^{14}, NR^{15}; N; O; and S;

- X^4 is selected from CR^{16}, NR^{17}; N; O; and S;

- each R^9 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; =O; and =S; wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

- W^1 is selected from $CR^{32}R^{32a}$; NR^{33}; O; S; and SO_2;

- each p and q is independently selected from 1 and 2, whereby p+q is selected from 2 and 3;

- cycle B is selected from aryl; and heterocycle; wherein said aryl and heterocycle can be unsubstituted or substituted with one or more Z^{1a};

- R^1 is selected from cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; heterocycle; arylalkyl; arylalkenyl; arylalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-heteroalkyl; heterocycle-heteroalkenyl; heterocycle-heteroalkynyl;

and wherein said cycloalkyl; cycloalkenyl; cycloalkynyl; aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl and heterocycle-heteroalkynyl can be unsubstituted or substituted with one or more Z^{1b};

- R^2 is selected from hydrogen; alkyl; cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl; heteroalkenyl; and heteroalkynyl;

and wherein said alkyl, cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl, heteroalkenyl, and heteroalkynyl, can be unsubstituted or substituted with one or more Z^{1c};

- each R^{12}, R^{14}, and R^{16} is independently selected from hydrogen; halogen; hydroxyl; sulfhydryl; trifluoromethyl; trifluoromethoxy; nitro; amino; cyano; alkyl; cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl;

wherein said alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, and heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

- R^{13}, R^{15}, and R^{17} is independently selected from hydrogen; hydroxyl; sulfhydryl; $-S(O)Z^2$; $-S(O)_2Z^3$; $-S(O)_2NZ^4Z^5$; trifluoromethyl; $-C(O)Z^3$; $-C(O)OZ^2$; $-C(O)NZ^4Z^5$; -C(O)H; alkyl; cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl;

wherein said alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

- each R^{32} and R^{32a} is independently selected from hydrogen; halogen; hydroxyl; sulfhydryl; =O; =S; trifluoromethyl; trifluoromethoxy; cyano; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; and heteroalkynyl; and wherein said alkyl, alkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, can be unsubstituted or substituted with one or more substituents selected from hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

- each R^{33} is independently selected from hydrogen; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; and heteroalkynyl; and wherein said alkyl, alkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, can be unsubstituted or substituted with one or more substituents selected from hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

- each Z^{1a}, Z^{1b}, and Z^{1c} is independently selected from the group consisting of halogen; hydroxyl; sulfhydryl; $-OZ^2$; =O; $-SZ^2$; =S; $-S(O)Z^2$; $-S(O)_2Z^3$; $-S(O)_2NZ^4Z^5$; trifluoromethyl; trifluoromethoxy; nitro; $-NZ^4Z^5$; $-NZ^4S(O)_2Z^2$; $-NZ^4C(O)Z^2$; $-NZ^4C(O)NZ^4Z^5$; cyano; $-C(O)Z^3$; $-C(O)OZ^2$; $-C(O)NZ^4Z^5$; -C(O)H; alkyl; cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; heterocycle; arylalkyl; arylalkenyl; arylalkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; heterocycle-heteroalkyl, heterocycle-heteroalkenyl; or heterocycle-heteroalkynyl;

and wherein said alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl, or heterocycle-heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

- each Z^2 is independently selected from alkyl; cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; heterocycle; arylalkyl; arylalkenyl; arylalkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; heterocycle-heteroalkyl; heterocycle-heteroalkenyl; or heterocycle-heteroalkynyl;

wherein said alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl, or heterocycle-heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, -O-alkyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

- each Z^3 is independently selected from hydroxyl; alkyl; cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; heterocycle; arylalkyl; arylalkenyl; arylalkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; heterocycle-heteroalkyl; heterocycle-heteroalkenyl; or heterocycle-heteroalkynyl;

wherein said alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl, or heterocycle-heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, -O-alkyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

- each Z^4 and Z^5 is independently selected from hydrogen; alkyl; cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; heterocycle; arylalkyl; arylalkenyl; arylalkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; heterocycle-heteroalkyl; heterocycle-heteroalkenyl; or heterocycle-heteroalkynyl;

wherein said alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl, or heterocycle-heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, -O-alkyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

and wherein Z^4 and Z^5 can be taken together in order to form a (5-, 6-, or 7-membered) heterocycle which can be unsubstituted or substituted with alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, hydroxyl, halogen, -SH, trifluoromethyl, -O-alkyl, $-OCF_3$, cyano, nitro, -C(O)OH or $-NH_2$;

and isomers (in particular stereo-isomers or tautomers), solvates, or salts (in particular pharmaceutically acceptable salts) thereof,

with the proviso that said compound is not

2-anilino-2-(4-tert-butylphenyl)-1-(2-phenyl-1-piperidyl)ethanone;

2-anilino-1-(2-phenyl-1-piperidyl)-2-[4-(trifluoromethyl)phenyl]ethanone;

2-anilino-2-(4-tert-butylphenyl)-1-(2-phenylazepan-1-yl)ethanone.

In another aspect of the present disclosure, there is provided compounds disclosed herein for use as a medicine.

In a further aspect of the present disclosure, there is provided compounds of formula (A), for use in the prevention or treatment of a flavivirus infection in an animal, mammal or human;



(A)

wherein,

- cycle A is selected from the group consisting of cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; wherein said cycloalkyl, cycloalkenyl, cycloalkynyl, aryl and heterocycle, can be unsubstituted or substituted with one or more substituents selected from alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, $-OCF_3$, cyano, nitro, -C(O)OH, $-NH_2$, NH(alkyl), or $N(alkyl)_2$;
- cycle C is a monocycle selected from



(a1) ;



(a2) ;



(a3) ;

wherein the wavy line (〰) indicates the point of attachment to the carbonyl of the main formula (A) and the hashed line (||||||||||) indicates the point of attachment to the cycle A of the

main formula (A);

- X^1 is selected from C; and N;

- X^2 is selected from CR^{12}; NR^{13}; N; O; and S;

- X^3 is selected from CR^{14}, NR^{15}; N; O; and S;

- X^4 is selected from CR^{16}, NR^{17}; N; O; and S;

- each R^3 and R^9 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; =O; and =S; wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

- each R^4 and R^5 is independently selected from hydrogen; halogen; hydroxyl; sulfhydryl; =O; =S; trifluoromethyl; trifluoromethoxy; cyano; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; and heteroalkynyl; and wherein said alkyl, alkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, can be unsubstituted or substituted with one or more substituents selected from hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

- W^1 is selected from $CR^{32}R^{32a}$; NR^{33}; O; S; and SO_2;

- each p and q is independently selected from 1 and 2, whereby p+q is selected from 2 and 3;

- cycle B is selected from aryl; and heterocycle; wherein said aryl and heterocycle can be unsubstituted or substituted with one or more Z^{1a};

- R^1 is selected from cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; heterocycle; arylalkyl; arylalkenyl; arylalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-heteroalkyl; heterocycle-heteroalkenyl; heterocycle-heteroalkynyl;

  and wherein said cycloalkyl; cycloalkenyl; cycloalkynyl; aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl and heterocycle-heteroalkynyl can be unsubstituted or substituted with one or more Z^{1b};

- R^2 is selected from hydrogen; alkyl; cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl; heteroalkenyl; and heteroalkynyl;

  and wherein said alkyl, cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl, heteroalkenyl, and heteroalkynyl, can be unsubstituted or substituted with one or more Z^{1c};

- each R^{12}, R^{14}, and R^{16} is independently selected from hydrogen; halogen; hydroxyl; sulfhydryl; trifluoromethyl; trifluoromethoxy; nitro; amino; cyano; alkyl; cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl;

  wherein said alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, and heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl,

hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, -OCF_3, cyano, nitro, -C(O)OH or NH_2;

- R^{13}, R^{15}, and R^{17} is independently selected from hydrogen; hydroxyl; sulfhydryl; -$S(O)Z^2$; -$S(O)_2Z^3$; -$S(O)_2NZ^4Z^5$; trifluoromethyl; -$C(O)Z^3$; -$C(O)OZ^2$; -$C(O)NZ^4Z^5$; -C(O)H; alkyl; cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl;

wherein said alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, -OCF_3, cyano, nitro, -C(O)OH or NH_2;

- each R^{32} and R^{32a} is independently selected from hydrogen; halogen; hydroxyl; sulfhydryl; =O; =S; trifluoromethyl; trifluoromethoxy; cyano; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; and heteroalkynyl; and wherein said alkyl, alkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, can be unsubstituted or substituted with one or more substituents selected from hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, -OCF_3, cyano, nitro, -C(O)OH or NH_2;

- each R^{33} is independently selected from hydrogen; alkyl; alkenyl; alkynyl; heteroalkyl; heteroalkenyl; and heteroalkynyl; and wherein said alkyl, alkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, can be unsubstituted or substituted with one or more substituents selected from hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, -OCF_3, cyano, nitro, -C(O)OH or NH_2;

- each Z^{1a}, Z^{1b}, and Z^{1c} is independently selected from the group consisting of halogen; hydroxyl; sulfhydryl; -OZ^2; =O; -SZ^2; =S; -$S(O)Z^2$; -$S(O)_2Z^3$; -$S(O)_2NZ^4Z^5$; trifluoromethyl; trifluoromethoxy; nitro; -NZ^4Z^5; -$NZ^4S(O)_2Z^2$; -$NZ^4C(O)Z^2$; -$NZ^4C(O)NZ^4Z^5$; cyano; -$C(O)Z^3$; -$C(O)OZ^2$; -$C(O)NZ^4Z^5$; -C(O)H; alkyl; cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; heterocycle; arylalkyl; arylalkenyl; arylalkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; heterocycle-heteroalkyl, heterocycle-heteroalkenyl; or heterocycle-heteroalkynyl;

and wherein said alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl, or heterocycle-heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, -OCF_3, cyano, nitro, -C(O)OH or NH_2;

- each Z^2 is independently selected from alkyl; cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; heterocycle; arylalkyl; arylalkenyl; arylalkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; heterocycle-heteroalkyl; heterocycle-heteroalkenyl; or heterocycle-heteroalkynyl;

wherein said alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl, or heterocycle-heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, -O-alkyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

- each Z^3 is independently selected from hydroxyl; alkyl; cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; heterocycle; arylalkyl; arylalkenyl; arylalkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; heterocycle-heteroalkyl; heterocycle-heteroalkenyl; or heterocycle-heteroalkynyl;

wherein said alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl, or heterocycle-heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, -O-alkyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

- each Z^4 and Z^5 is independently selected from hydrogen; alkyl; cycloalkyl; alkenyl; cycloalkenyl; alkynyl; cycloalkynyl; heteroalkyl; heteroalkenyl; heteroalkynyl; aryl; heterocycle; arylalkyl; arylalkenyl; arylalkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; heterocycle-heteroalkyl; heterocycle-heteroalkenyl; or heterocycle-heteroalkynyl;

wherein said alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl, or heterocycle-heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, -O-alkyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

and wherein Z^4 and Z^5 can be taken together in order to form a (5-, 6-, or 7-membered) heterocycle which can be unsubstituted or substituted with alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, hydroxyl, halogen, -SH, trifluoromethyl, -O-alkyl, $-OCF_3$, cyano, nitro, -C(O)OH or $-NH_2$;

and isomers (in particular stereo-isomers or tautomers), solvates, or salts (in particular pharmaceutically acceptable salts) ~~or prodrugs~~ thereof.

In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient an

effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof.

In a further aspect of the present disclosure, there is provided a method for the preparation of a compound disclosed herein comprising the step of

- reacting an imine with an aldehyde under umpolung conditions in the presence of a thiazolium catalyst to obtain the desired compounds of the present disclosure; or
- reacting a ketone derivative having a methylene adjacent to the carbonyl under halogenation conditions to obtain an alpha-halogenoketone, and
- substitute the previously obtained alpha-halogenoketone with amines to obtain the desired compounds of the present disclosure; or
- reacting a heterocyclicamine with 2-halogeno-acetic acid halide to obtain an alpha-halogenoamide derivative, and
- substitute the previously obtained alpha-halogenoamide with amines to obtain the desired compounds of the present disclosure.

In another aspect of the present disclosure, there is provided a use of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of a Flaviviral infection in humans.

DETAILED DESCRIPTION OF THE INVENTION

The present invention will be described with respect to particular embodiments but the invention is not limited thereto.

Preferred statements (features) and embodiments of the compounds and processes of this invention are set herein. Each statements and embodiments of the invention so defined may be combined with any other statement and/or embodiments unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.

Numbered statements of this invention are:

1. A compound of formula (A),



(A)

wherein,

- cycle A is selected from the group consisting of cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; wherein said cycloalkyl, cycloalkenyl, cycloalkynyl, aryl and heterocycle, can be unsubstituted or substituted with one or more substituents selected from alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, $-OCF_3$, cyano, nitro, -C(O)OH, $-NH_2$, NH(alkyl), or $N(alkyl)_2$;
- cycle C is a monocycle selected from

arylalkyl; arylalkenyl; arylalkynyl; arylheteroalkyl; arylheteroalkenyl; arylheteroalkynyl; heterocycle-alkyl; heterocycle-alkenyl; heterocycle-alkynyl; heterocycle-heteroalkyl; heterocycle-heteroalkenyl; or heterocycle-heteroalkynyl;

wherein said alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl, or heterocycle-heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, -O-alkyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

and wherein Z^4 and Z^5 can be taken together in order to form a (5-, 6-, or 7-membered) heterocycle which can be unsubstituted or substituted with alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, hydroxyl, halogen, -SH, trifluoromethyl, -O-alkyl, $-OCF_3$, cyano, nitro, -C(O)OH or $-NH_2$;

and isomers (in particular stereo-isomers or tautomers), solvates, or salts (in particular pharmaceutically acceptable salts) ~~or prodrugs~~ thereof,

with the proviso that said compound is not

2-anilino-2-(4-tert-butylphenyl)-1-(2-phenyl-1-piperidyl)ethanone;

2-anilino-1-(2-phenyl-1-piperidyl)-2-[4-(trifluoromethyl)phenyl]ethanone;

2-anilino-2-(4-tert-butylphenyl)-1-(2-phenylazepan-1-yl)ethanone.

2. The compounds of claim 1, wherein cycle C is selected from the following group of cycles

heterocycle-heteroalkenyl; or heterocycle-heteroalkynyl;

wherein said alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heterocycle, arylalkyl, arylalkenyl, arylalkynyl, arylheteroalkyl, arylheteroalkenyl, arylheteroalkynyl, heterocycle-alkyl, heterocycle-alkenyl, heterocycle-alkynyl, heterocycle-heteroalkyl, heterocycle-heteroalkenyl, or heterocycle-heteroalkynyl can be unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, -O-alkyl, $-OCF_3$, cyano, nitro, -C(O)OH or NH_2;

and wherein Z^4 and Z^5 can be taken together in order to form a (5-, 6-, or 7-membered) heterocycle which can be unsubstituted or substituted with alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, hydroxyl, halogen, -SH, trifluoromethyl, -O-alkyl, $-OCF_3$, cyano, nitro, -C(O)OH or $-NH_2$;

and isomers (in particular stereo-isomers or tautomers), solvates, or salts (in particular pharmaceutically acceptable salts) ~~or prodrugs~~ thereof.

8. The compounds according to claim 7, wherein cycle C is selected from the following group of cycles



- reacting an imine with an aldehyde under umpolung conditions in the presence of a thiazolium catalyst to obtain the desired compounds of the invention; or

- reacting a ketone derivative having a methylene adjacent to the carbonyl under halogenation conditions to obtain an alpha-halogenoketone, and
- substitute the previously obtained alpha-halogenoketone with amines to obtain the desired compounds of the invention; or

- reacting a heterocyclicamine with 2-halogeno-acetic acid halide to obtain an alpha-halogenoamide derivative, and
- substitute the previously obtained alpha-halogenoamide with amines to obtain the desired compounds of the invention.

14. Use of a compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of a Flaviviral infection in humans.

15. The use according to claim 14, wherein the compound is in combination with one or more other medicines.

16. The use according to any one of claims 13 or 14, wherein the Flaviviral infection is an infection by the Dengue virus or yellow fever virus.